Capstone turns a former biotech shell into a roll-up business selling stone veneer and masonry supplies, aiming to stitch together many small regional distributors into a larger, national platform. New in-house product lines, expansion into new regions, and a cleaner cost base could lift profitability—but it depends on pulling off acquisitions without overreaching in a construction market that can cool quickly.Read more

Silo Pharma is betting on a mix of familiar medicines and psychedelic-inspired science to tackle conditions like PTSD, chronic pain, Alzheimer’s, and multiple sclerosis—using novel delivery methods like nasal sprays and tiny implants. The big question is whether its early test results and research partners can translate into human trials before funding needs and regulatory hurdles slow things down.Read more

Apple faces a fresh hit from trade tensions because many iPhones are built in China, but the company is pushing production to other countries and leaning more on its fast-growing services business. The next chapter hinges on whether Apple can blunt tariff pressure while turning its push into artificial intelligence into new reasons for customers to stick around and spend.Read more